COMPANY PROFILE

Rheos Medicines

A biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease

Cambridge, United StatesFounded 2018Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2018

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Rheos Medicines

Rheos Medicines is pioneering the field of immunometabolism to develop innovative, precision medicines aimed at treating patients with severe immune-mediated diseases and cancer. The company leverages cutting-edge research to translate insights in immunometabolism into novel therapeutic solutions. Rheos Medicines primarily serves patients suffering from complex immune system disorders and various forms of cancer, operating within the biopharmaceutical market. The business model is centered around research and development, with revenue generated through the commercialization of its proprietary treatments and potential collaborations with other pharmaceutical companies. The company's approach is highly specialized, focusing on the intersection of immunology and metabolism to create targeted therapies that address unmet medical needs.

Source: Dealroom company data

At a glance

Status: Closed
Founded: 2018
Headquarters: Cambridge, United States
Employees: 29
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Rheos Medicines.

See all news

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Mar 2018	$60M	$240M	Third Rock Ventures	—
SPINOUTOther financing	Jan 2018	$0	—	Max Planck Innovation · Yale University · Max Planck Society	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Rheos Medicines website traffic

Latest recorded traffic for Rheos Medicines is 490 monthly website visits, down 55.5% over the last three months. Rheos Medicines's team grew 16% over the past year.

Latest monthly visits490 3-month web change-55.5% 1-year team growth+16%

Monthly website visitsOct 2017–Jan 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PAPanacea-mlExplainable-AI Platform to Streamline Clinical Trial Design	Ra'anana, Israel	Operational	2	$1M	$3.7M
DCDCGenCreating better life for patients with personalized	Seoul, South Korea	Operational
OTOlatec TherapeuticsLeaders in the Clinical Development of Inflammasome Therapeutics	New York City, United States	Operational
CACannaSoul AnalyticsInnovative therapeutics from natural compounds, bridging botanical medicine and the pharmaceutical industry	Caesarea, Israel	Operational
STSeed TherapeuticsPioneering the science of improving human health	New York City, United States	Operational
MTMarch TherapeuticsBuilding scalable therapeutics platform with mitochondrial genome editors	Cambridge, United States	Operational
CTConvergent TherapeuticsConvergent Therapeutics is developing next-generation radiopharmaceutical therapies to treat prostate cancer and beyond	Cambridge, United States	Operational
CTCERES BRAIN TherapeuticsNeuron-rescuing therapies for neurological bioenergetic diseases	Paris, France	Operational